In JACC, Oct 2017, (Jl of the American College of Cardiology), there was a beginning of a series on colchicine and heart attack/stroke prevention. This focus on cardiovascular inflammation (CV) inflammation was started again in June of 2017. It was tripped off by the announcement of the CANTOS trial by Paul Ridker.

I review the cellular view of plaque inflammation. Then I talk about colchicine. Colchicine was first recorded as a treatment for arthritis, rheumatism, which is caused by similar inflammation of the joints. I review the Clinical Trials.gov site on the COLCOT study, an upcoming trial using colchicine.